Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells

British Journal of Pharmacology

Volumn 159, Issue 6, 2010, Pages 1294-1303

  Jougasaki, Michihisa ^a   Ichiki, Tomoko ^a,b   Takenoshita, Yoko ^a   Setoguchi, Manabu ^a  

^a NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Atherosclerosis; Cells; Endothelium; Inflammation; Interleukin 6; MCP 1, JAK; STAT; Statin

Indexed keywords

ATORVASTATIN; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; MEVALONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE TYK2; SIMVASTATIN; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN;

ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; CELL MIGRATION; CELL NUCLEUS; CELL STIMULATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; VASCULAR ENDOTHELIUM;

AORTA; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; JANUS KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 77949354684     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00612.x     Document Type: Article

References (35)

1. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ et al. (1999). Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19: 1518-1525.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R et al. (1998). HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18: 1671-1678.
4. Biswas P, Delfanti F, Bernasconi S, Mengozzi M, Cota M, Polentarutti N et al. (1998). Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91: 258-265.
5. Boring L, Gosling J, Cleary M, Charo IF (1998). Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897.
6. Casey PJ (1995). Protein lipidation in cell signaling. Science 268: 221-225.
7. Charo IF, Taubman MB (2004). Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866.
8. Coletta I, Soldo L, Polentarutti N, Mancini F, Guglielmotti A, Pinza M et al. (2000). Selective induction of MCP-1 in human mesangial cells by the IL-6/sIL-6R complex. Exp Nephrol 8: 37-43.
9. Goldstein JL, Brown MS (1990). Regulation of the mevalonate pathway. Nature 343: 425-430.
10. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG et al. (1999). MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103: 773-778.
11. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ et al. (1998). 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490-500.
12. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998). Interleukin-6-type cytokine signalling through the gp130/ JAK/STAT pathway. Biochem J 334: 297-314.
13. Hess S, Smola H, Sandaradura De Silva U, Hadaschik D, Kube D, Baldus SE et al. (2000). Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production. J Immunol 165: 1939-1948.
14. Ichiki T, Jougasaki M, Setoguchi M, Imamura J, Nakashima H, Matsuoka T et al. (2008). Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am J Physiol Heart Circ Physiol 294: H750-H763.
15. Jougasaki M, Schirger JA, Simari RD, Burnett JC Jr (1998). Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension 32: 917-922.
16. Kaneider NC, Egger P, Dunzendorfer S, Noris P, Balduini CL, Gritti D et al. (2002). Reversal of thrombin-induced deactivation of CD39/ ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 22: 894-900.
17. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ et al. (2003). Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108: 1368-1374.
18. Libby P (2002). Inflammation in atherosclerosis. Nature 420: 868-874.
19. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L (2001). HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159: 27-33.
20. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K et al. (1993). IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260: 1808-1810.
21. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T et al. (2002). Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 22: 115-120.
22. Rane SG, Reddy EP (2002). JAKs, STATs and Src kinases in hematopoiesis. Oncogene 21: 3334-3358.
23. Rolfe BE,Worth NF,World CJ, Campbell JH, Campbell GR (2005). Rho and vascular disease. Atherosclerosis 183: 1-16.
24. Rollins BJ (1997). Chemokines. Blood 90: 909-928.
25. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P et al. (1997). Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6: 315-325.
26. Ross R (1999). Atherosclerosis - an inflammatory disease. New Engl J Med 340: 115-126.
27. Rott D, Zhu J, Zhou YF, Burnett MS, Zalles-Ganley A, Epstein SE (2003). IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 170: 223-228.
28. Schall TJ, Bacon KB (1994). Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 6: 865-873.
29. Takemoto M, Liao JK (2001). Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719.
30. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y et al. (1993). Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90: 11924-11928.
31. Thunyakitpisal PD, Chaisuparat R (2004). Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 94: 403-409.
32. Tse FL, Jaffe JM, Troendle A (1992). Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32: 630-638.
33. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S et al. (2006). Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188: 51-58.
34. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ (2001). Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 69: 959-962.
35. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ et al. (1991). Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88: 5252-5256.